CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: EC 2.5.1.15 (dihydropteroate synthase) inhibitor
Accession: CHEBI:50502
browse the term
Definition: An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate.
Synonyms: related_synonym: (2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitor; (2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitors; 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitor; 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitors; 7,8-dihydropteroate synthase inhibitor; 7,8-dihydropteroate synthase inhibitors; 7,8-dihydropteroate synthetase inhibitor; 7,8-dihydropteroate synthetase inhibitors; 7,8-dihydropteroic acid synthetase inhibitor; 7,8-dihydropteroic acid synthetase inhibitors; DHPS inhibitor; DHPS inhibitors; EC 2.5.1.15 (dihydropteroate synthase) inhibitors; EC 2.5.1.15 inhibitor; EC 2.5.1.15 inhibitors; dihydropteroate diphosphorylase inhibitor; dihydropteroate diphosphorylase inhibitors; dihydropteroate pyrophosphorylase inhibitor; dihydropteroate pyrophosphorylase inhibitors; dihydropteroate synthase inhibitor; dihydropteroate synthase inhibitors; dihydropteroate synthetase inhibitor; dihydropteroate synthetase inhibitors; dihydropteroic synthetase inhibitor; dihydropteroic synthetase inhibitors
xref: Wikipedia:Dihydropteroate_synthase_inhibitor
G
Ins2
insulin 2
increases secretion
ISO
Trimethoprim, Sulfamethoxazole Drug Combination results in increased secretion of INS protein modified form
CTD
PMID:14714756
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
G
Ddit4
DNA-damage-inducible transcript 4
multiple interactions increases expression
ISO
[Folic Acid deficiency co-treated with succinylsulfathiazole] results in decreased expression of DDIT4 protein succinylsulfathiazole results in increased expression of DDIT4 protein
CTD
PMID:33957263
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
G
Eif4ebp1
eukaryotic translation initiation factor 4E binding protein 1
decreases phosphorylation
ISO
succinylsulfathiazole results in decreased phosphorylation of EIF4EBP1 protein
CTD
PMID:33957263
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
G
Mtor
mechanistic target of rapamycin kinase
decreases phosphorylation
ISO
succinylsulfathiazole results in decreased phosphorylation of MTOR protein
CTD
PMID:33957263
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
G
Pdpk1
3-phosphoinositide dependent protein kinase-1
multiple interactions decreases expression
ISO
Folic Acid deficiency inhibits the reaction [succinylsulfathiazole results in decreased expression of PDPK1 protein]
CTD
PMID:33957263
NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623
G
Akr1b10
aldo-keto reductase family 1 member B10
increases expression
ISO
4-nitrososulfamethoxazole results in increased expression of AKR1B10 mRNA
CTD
PMID:28444390
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
G
Hmgb1
high mobility group box 1
increases secretion
ISO
4-nitrososulfamethoxazole results in increased secretion of HMGB1 protein
CTD
PMID:28444390
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
G
Ifng
interferon gamma
increases secretion
ISO
4-nitrososulfamethoxazole results in increased secretion of IFNG protein
CTD
PMID:22331489
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
G
Il13
interleukin 13
increases secretion
ISO
4-nitrososulfamethoxazole results in increased secretion of IL13 protein
CTD
PMID:22331489
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
G
Il1a
interleukin 1 alpha
increases secretion
ISO
4-nitrososulfamethoxazole results in increased secretion of IL1A protein
CTD
PMID:28444390
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
G
Il1b
interleukin 1 beta
increases secretion
ISO
4-nitrososulfamethoxazole results in increased secretion of IL1B protein
CTD
PMID:28444390
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il5
interleukin 5
increases secretion
ISO
4-nitrososulfamethoxazole results in increased secretion of IL5 protein
CTD
PMID:22331489
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
G
Il6
interleukin 6
increases secretion
ISO
4-nitrososulfamethoxazole results in increased secretion of IL6 protein
CTD
PMID:28444390
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Mpo
myeloperoxidase
affects binding multiple interactions
ISO
4-nitrososulfamethoxazole binds to MPO protein [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Sulfamethoxazole] which results in increased chemical synthesis of 4-nitrososulfamethoxazole
CTD
PMID:25531135
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
G
Nqo1
NAD(P)H quinone dehydrogenase 1
increases expression
ISO
4-nitrososulfamethoxazole results in increased expression of NQO1 mRNA
CTD
PMID:28444390
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
G
Srxn1
sulfiredoxin 1
increases expression
ISO
4-nitrososulfamethoxazole results in increased expression of SRXN1 mRNA
CTD
PMID:28444390
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
G
Tnf
tumor necrosis factor
increases secretion
ISO
4-nitrososulfamethoxazole results in increased secretion of TNF protein
CTD
PMID:28444390
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Txnrd1
thioredoxin reductase 1
increases expression
ISO
4-nitrososulfamethoxazole results in increased expression of TXNRD1 mRNA
CTD
PMID:28444390
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
G
Hmbs
hydroxymethylbilane synthase
decreases activity
EXP
Sulfacetamide decreases activity of purified Hmbs protein
RGD
PMID:6893114
RGD:26923963
NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957
G
Cyp2c79
cytochrome P450, family 2, subfamily c, polypeptide 79
increases hydroxylation
ISO
CYP2C8 protein results in increased hydroxylation of Sulfadiazine
CTD
PMID:15843491
G
Grin1
glutamate ionotropic receptor NMDA type subunit 1
decreases expression
ISO
Sulfadiazine results in decreased expression of GRIN1 mRNA
CTD
PMID:34748853
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
G
Hmbs
hydroxymethylbilane synthase
decreases activity
EXP
Sulfadiazine decreases activity of purified Hmbs protein
RGD
PMID:6893114
RGD:26923963
NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957
G
Il6
interleukin 6
multiple interactions
ISO
[Sulfadiazine co-treated with Pyrimethamine] results in decreased expression of IL6 protein; [Trimethoprim co-treated with Sulfadiazine] results in increased expression of IL6 protein
CTD
PMID:10888991 PMID:37722575
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Lpo
lactoperoxidase
decreases expression
ISO
Sulfadiazine results in decreased expression of LPO mRNA
CTD
PMID:34748853
NCBI chr10:72,606,950...72,626,220
Ensembl chr10:72,606,944...72,626,535
G
Mtor
mechanistic target of rapamycin kinase
decreases expression
ISO
Sulfadiazine results in decreased expression of MTOR mRNA
CTD
PMID:34748853
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
G
Nat2
N-acetyltransferase 2
increases acetylation
ISO
NAT2 protein results in increased acetylation of Sulfadiazine
CTD
PMID:15843491
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
G
Olig2
oligodendrocyte transcription factor 2
decreases expression
ISO
Sulfadiazine results in decreased expression of OLIG2 mRNA
CTD
PMID:34748853
NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152
G
Shank2
SH3 and multiple ankyrin repeat domains 2
decreases expression
ISO
Sulfadiazine results in decreased expression of SHANK2 mRNA
CTD
PMID:34748853
NCBI chr 1:199,146,210...199,590,962
Ensembl chr 1:199,169,429...199,589,394
G
Slc6a4
solute carrier family 6 member 4
decreases expression
ISO
Sulfadiazine results in decreased expression of SLC6A4 mRNA
CTD
PMID:34748853
NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
increases activity
ISO
Sulfamethazine results in increased activity of CYP3A4 protein
CTD
PMID:12065438
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Nat2
N-acetyltransferase 2
increases acetylation increases metabolic processing affects acetylation
ISO
NAT2 protein results in increased acetylation of Sulfamethazine NAT2 protein results in increased metabolism of Sulfamethazine NAT2 polymorphism affects the acetylation of Sulfamethazine
CTD
PMID:12222688 PMID:15627487 PMID:15880531 PMID:21317369 PMID:28516247 PMID:30358977 More...
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
G
Nr1i2
nuclear receptor subfamily 1, group I, member 2
increases activity
ISO
Sulfamethazine results in increased activity of NR1I2 protein
CTD
PMID:12065438
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
G
Il1b
interleukin 1 beta
multiple interactions
ISO
Sulfamethizole inhibits the reaction [Poloxalene results in increased expression of IL1B protein]
CTD
PMID:36799065
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Mtor
mechanistic target of rapamycin kinase
multiple interactions
ISO
Sulfamethizole inhibits the reaction [Poloxalene results in increased expression of MTOR protein]
CTD
PMID:36799065
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
G
Tnf
tumor necrosis factor
multiple interactions
ISO
Sulfamethizole inhibits the reaction [Poloxalene results in increased expression of TNF protein]
CTD
PMID:36799065
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Abcb11
ATP binding cassette subfamily B member 11
decreases activity multiple interactions
ISO
Sulfamethoxazole results in decreased activity of ABCB11 protein Sulfamethoxazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
CTD
PMID:24014644
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
G
Acan
aggrecan
decreases expression
EXP
Sulfamethoxazole results in decreased expression of ACAN mRNA
CTD
PMID:26107568
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
G
Alb
albumin
multiple interactions
ISO
Sulfamethoxazole metabolite binds to and results in increased metabolism of ALB protein
CTD
PMID:19358516
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
G
Col2a1
collagen type II alpha 1 chain
decreases expression
EXP
Sulfamethoxazole results in decreased expression of COL2A1 mRNA
CTD
PMID:26107568
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
multiple interactions
EXP
[SOD2 co-treated with CYP3A4] affects the susceptibility to Sulfamethoxazole
CTD
PMID:19501153
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Gstp1
glutathione S-transferase pi 1
multiple interactions
ISO
Sulfamethoxazole metabolite binds to and results in increased metabolism of GSTP1 protein
CTD
PMID:19358516
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
G
Ifng
interferon gamma
increases secretion
ISO
Sulfamethoxazole analog results in increased secretion of IFNG protein
CTD
PMID:15588915
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
G
Il5
interleukin 5
increases secretion
ISO
Sulfamethoxazole analog results in increased secretion of IL5 protein
CTD
PMID:15588915
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
G
Mir155
microRNA 155
increases expression
ISO
Sulfamethoxazole results in increased expression of MIR155 mRNA
CTD
PMID:29644860
NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718
G
Mir18a
microRNA 18a
increases expression
ISO
Sulfamethoxazole results in increased expression of MIR18A mRNA
CTD
PMID:29644860
NCBI chr15:92,180,765...92,180,860
Ensembl chr15:92,180,765...92,180,860
G
Mir21
microRNA 21
increases expression
ISO
Sulfamethoxazole results in increased expression of MIR21 mRNA
CTD
PMID:29644860
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
G
Mpo
myeloperoxidase
multiple interactions
ISO
[[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Sulfamethoxazole] which results in increased chemical synthesis of 4-nitrososulfamethoxazole; [MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Sulfamethoxazole
CTD
PMID:25531135
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
G
Nat2
N-acetyltransferase 2
increases metabolic processing
ISO
NAT2 protein results in increased metabolism of Sulfamethoxazole
CTD
PMID:16847467
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
G
Phyh
phytanoyl-CoA 2-hydroxylase
decreases expression
ISO
Sulfamethoxazole results in decreased expression of PHYH mRNA
CTD
PMID:15342952
NCBI chr17:73,329,461...73,346,359
Ensembl chr17:73,329,082...73,346,409
G
Pir
pirin
increases expression
ISO
Sulfamethoxazole results in increased expression of PIR mRNA
CTD
PMID:22609641
NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218
G
RT1-M3-1
RT1 class Ib, locus M3, gene 1
affects expression
ISO
Sulfamethoxazole affects the expression of HLA-G mRNA
CTD
PMID:25811541
NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
G
Sod2
superoxide dismutase 2
multiple interactions
EXP
[SOD2 co-treated with CYP3A4] affects the susceptibility to Sulfamethoxazole
CTD
PMID:19501153
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
G
Sox9
SRY-box transcription factor 9
decreases expression
EXP
Sulfamethoxazole results in decreased expression of SOX9 mRNA
CTD
PMID:26107568
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
G
Cyb5b
cytochrome b5 type B
multiple interactions
ISO
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CTD
PMID:25170804
NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249
G
Cyb5r3
cytochrome b5 reductase 3
multiple interactions
ISO
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CTD
PMID:25170804
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
G
Mtarc1
mitochondrial amidoxime reducing component 1
multiple interactions
ISO
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CTD
PMID:25170804
NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796
G
Mtarc2
mitochondrial amidoxime reducing component 2
multiple interactions
ISO
[MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CTD
PMID:25170804
NCBI chr13:96,362,810...96,397,284
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all